Background: Proteus syndrome is a rare overgrowth disorder that almost always affects the skin.
P roteus syndrome is a rare overgrowth disorder affecting multiple tissues including bone, soft tissue, and skin. The syndrome was described by Cohen and Hayden 1 in 1979 and given its current name by Wiedemann et al 2 in 1983. As of October 2004, there were fewer than 100 published cases fulfilling current diagnostic criteria worldwide. 3 Diagnosis is made by evidence of 3 mandatory general criteria, including sporadic occurrence, mosaic distribution of lesions, and progressive course. These must be accompanied by specific criteria, several of which comprise skin lesions. 4 The cerebriform connective tissue nevus (CCTN) is one of the most characteristic skin findings. It commonly occurs on the soles of the feet, and is frequently a cause of pain, pruritus, infection, bleeding, exudation, odor, and walking impairment. 5 Patients without a CCTN may be given a diagnosis based on the presence of other specific features, but it is typical to have a CCTN and one or more additional skin findings, such as linear verrucous epidermal nevus, dysregulated adipose tissue (lipomas and/or lipohypoplasia), and vascular malformations (capillary, venous, lymphatic, and mixed). Other skin abnormalities, not in the diagnostic criteria but nonetheless associated with Proteus syndrome, include hyperpigmented or hypopigmented macules, patches of dermal hypoplasia, localized hypertrichosis, thick or thin nails, and areas of lighter-colored scalp hair. Progression is a mandatory feature for the diagnosis of Proteus syndrome but little is known about the natural history of the skin lesions, whether different lesions progress at different rates, and if the rate of progression is affected by age. In an earlier study, we assessed the progression of skin lesions using a questionnaire. Most patients or their caregivers reported progressive growth in the CCTN and subcutaneous lipomas, whereas the linear verrucous epidermal nevus and vascular malformations tended not to spread to new areas. 5 In the current study we used serial photographs to study changes in the extent of the skin lesions.
METHODS
In all, 36 patients were evaluated at the National Institutes of Health after enrolling in protocol 94-HG-0132. They met diagnostic criteria for Proteus syndrome as listed in Table I . Each patient had a complete skin examination and documentation of lesions by photography. Skin manifestations of some patients were reported previously. 5, 6 Sixteen patients were included in the longitudinal study as they had two or more visits at least 6 months apart with repeated photographs. Photographs were evaluated retrospectively for interval changes, using a semiquantitative scale for the connective tissue nevus (Table II) . Change in the CCTN score over time was estimated using a mixed linear regression model with patientspecific random intercepts. The age and status (adult or child) and their interaction were included in the model as fixed effects. The mixed model analysis module in a software program (SPSS, Version 14, SPSS Inc, Chicago, IL) was used to estimate the model.
RESULTS
There were 14 female and 22 male patients with age at first visit ranging from 1 to 56 years (mean age 14 6 13 years). Skin lesions associated with Proteus syndrome were observed in all patients (Table III) . The frequencies of these lesions were similar to those previously reported. 6 Sixteen patients were studied longitudinally for an average of 53 months. At presentation, the CCTN in 9 patients was a solitary plaque on one or both soles (4 with $ 1 separate papules or plaques on the toes) and 7 patients had multifocal plaques (4 with toe lesions). The CCTN grew by expansion and development of new lesions. Expansion was evident when a CCTN gradually overtook previously uninvolved skin of the sole, with the convoluted ridges of the CCTN increasing in size and number (Figs 1 and 2) .
Nearly all CCTNs in children showed expansion, and 3 children also developed apparently distinct lesions during the study period. New lesions appeared in areas that were previously uninvolved (Fig 1, E to H ) or had barely detectable involvement (Fig 2, C, arrow) . Discrete lesions also grew until they coalesced (Fig 2, A to C ). All patients younger than 20 years showed progression of the CCTN. One child, in whom the CCTN was unusual in that it involved the chest and abdomen, did not show an increase in the CCTN score during the study period, but progression was clearly evident in the first 4 years of his life. 7 Little or no progression was observed in the 3 adults (Fig 3) . Mixed model analysis indicated that the CCTN score increased on average by 1.24 points per year in those younger than 20 years (P\.001). This rate of increase was significantly greater than in adult patients (P \.001), in whom lesions increased by 0.05 points per year (P = .78).
Lipomas increased in size, number, or both in 8 of 10 children with lipomas. Linear verrucous epidermal nevi were stable in size but became darker over time in 4 of 10 children, and one child developed small new epidermal nevus papules between ages 3 and 6 years. Capillary vascular malformations remained stable in extent. Venous varicosities on the legs gradually became more prominent.
DISCUSSION
A mandatory criterion for the diagnosis of Proteus syndrome is a progressive course. This clinical criterion refers primarily to the skeletal system, in which patients experience distorting and disproportionate overgrowth of bones. 8 Here we show that progression throughout childhood is a consistent feature of the CCTN.
The typical course for the Proteus CCTN is for one or a few lesions to appear on the sole or soles at The cerebriform connective tissue nevus may not be present at birth but grows throughout childhood. Periodic followup is needed to manage complications of pain, skin breakdown, and walking impairment.
CAPSULE SUMMARY
about 2 years of age, although lesions may also appear in other areas of the body. 6 These slowly spread to previously uninvolved skin and grow thicker, becoming rubbery masses that tightly abut each other forming deep folds. It is these deep folds, resembling sulci, which led to the designation of the nevus as cerebriform. New lesions may develop elsewhere on the foot, eventually expanding to coalesce with other lesions. Once it reaches the sides of the foot, the CCTN may extend proximally around the foot, creating a progressively deeper fold between normal-appearing skin and the CCTN. When lesions occur on the toes, they appear as pale firm nodules that grow and may distort the nail. This type of postnatal disproportionate growth is distinct from that observed in other overgrowth syndromes. In patients with hemihyperplasia-multiple lipomatosis syndrome 9 or congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome), 10 the plantar surfaces may be overgrown at birth, but they are softer and compressible, have wrinkles rather than deep folds, and tend to grow with the child rather than disproportionately as in Proteus syndrome.
The scoring system we used provides strong evidence for progression of the CCTN in children with Proteus syndrome. It is only semiquantitative, however, and should not be used to conclude that the rate of growth of the CCTNs was linear or that it was similar in all children. Also, it is not inevitable that all CCTNs progress to involve the entire sole, because the 3 adults in this study had stable areas of J AM ACAD DERMATOL VOLUME 63, NUMBER 5 sparing. The adults tended to have lower CCTN scores than the children. This may reflect an overall lower disease severity for those who survive into adulthood. 6 Further longitudinal studies with more accurate volume measurements and more adult patients are required to better predict the growth of the Proteus CCTN.
Currently, there is no medical therapy that slows the growth of the CCTN, 11 and surgery is discouraged because of recurrence and painful scarring that may make walking impossible. 12 However, there is one report in the medical literature of a patient with bilateral plantar CCTN who underwent successful surgical removal of the CCTN with skin grafting. 13 New treatments are urgently needed, as these lesions are disfiguring and cause functional impairment. Patients encounter difficulties with foot hygiene, which can lead to odor and recurrent bacterial and fungal infections. Shoes may need to be modified and custom orthoses designed to help prevent blisters and skin breakdown.
One approach to medical therapy would be to target the abnormal cells that contribute to the growth of the CCTN. The CCTN of Proteus syndrome has decreased fibroblasts, variable thick collagen bundles in a disorganized pattern, sparse fragmented elastic fibrils, and increased fat and sweat glands in the reticular dermis.
14 It would appear that the plantar fibroblasts are defective, and investigations into fibroblasts grown from a CCTN in one patient documented decreased collagenase expression. 13 The genetic basis for these cellular abnormalities is unknown. Proteus syndrome appears to result from mosaicism, 15 making it especially challenging to identify the causative mutation or mutations. Mutations in PTEN have been documented in several children with an overgrowth syndrome with features of Proteus syndrome, 16 but the diagnosis of Proteus syndrome has been disputed. 17, 18 Genetic analysis may have therapeutic implications, as one child with life-threatening overgrowth caused by a germline PTEN mutation showed decreased size of soft-tissue masses in the mediastinum and pelvis during treatment with oral rapamycin. 19 This promising result needs to be confirmed for others with PTEN hamartoma tumor syndrome. It provides hope that further investigations into the genetic and molecular abnormalities in patients with Proteus syndrome will provide clues leading to a targeted therapy. We thank Cara Olsen for statistical analysis. 
